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Cholesterol is essential for membrane synthesis;
however, the mechanisms that link cellular lipid me-
tabolism to proliferation are incompletely under-
stood. We demonstrate here that cellular cholesterol
levels in dividing T cells are maintained in part
through reciprocal regulation of the LXR and SREBP
transcriptional programs. T cell activation triggers
induction of the oxysterol-metabolizing enzyme
SULT2B1, consequent suppression of the LXR path-
way for cholesterol transport, and promotion of the
SREBP pathway for cholesterol synthesis. Ligation
of LXRduring T cell activation inhibitsmitogen-driven
expansion, whereas loss of LXRb confers a prolifera-
tive advantage. Inactivation of the sterol transporter
ABCG1 uncouples LXR signaling from proliferation,
directly linking sterol homeostasis to the antipro-
liferative action of LXR. Mice lacking LXRb exhibit
lymphoid hyperplasia and enhanced responses to
antigenic challenge, indicating that proper regulation
of LXR-dependent sterol metabolism is important
for immune responses. These results implicate LXR
signaling in a metabolic checkpoint that modulates
cell proliferation and immunity.
INTRODUCTION
The capacity of lymphocytes to undergo rapid expansion in re-
sponse to antigenic challenge is essential for adaptive immunity.
Mounting evidence suggests that metabolism plays a key role in
the determination of lymphocyte responses. For example, acti-
vated T lymphocytes are functionally glycolytic despite sufficient
oxygen tension (Fox et al., 2005). As a consequence of this met-
abolic program, T cell activation requires high glucose availabil-ity (Roos and Loos, 1973). In the absence of sufficient glucose,
T cells fail to proliferate, and they undergo apoptosis (Alves
et al., 2006; Rathmell et al., 2000; Vander Heiden et al., 2001).
The influence of cellular lipid metabolism on immune responses,
however, is poorly understood.
Cholesterol is an important component of cell membranes and
has long been recognized to be necessary for cell growth and
proliferation (Brown and Goldstein, 1974; Chen et al., 1975;
Chen et al., 1974). Early studies defined a relationship between
the pathway for de novo sterol synthesis and movement through
the cell cycle in lymphocytes. Blocking ofmevalonate production
with certain cholesterol derivatives or HMG-CoA reductase in-
hibitors (statins) inhibits DNA synthesis and mitosis (Chakrabarti
and Engleman, 1991; Chen et al., 1975). A complicating factor in
these studies, however, is the requirement for the mevalonate
pathway in production of nonsterol mevalonate derivatives
such as geranylgeraniol and farnesol. Indeed, much of the immu-
nomodulatory effects of statins have been attributed to the biol-
ogy of these products (Kwak et al., 2000; Weitz-Schmidt et al.,
2001). The question of whether intracellular cholesterol distribu-
tion or availability represents a dynamic signal for control of
immune responses has not been adequately explored, and the
molecular mechanisms that link lipid metabolism to cellular
growth and the cell-cycle machinery remain unknown.
The liver X receptors (LXRa and LXRb) are members of the nu-
clear receptor superfamily that regulate cholesterol homeosta-
sis. The endogenous activators of these receptors are oxysterols
and intermediates in the cholesterol biosynthetic pathway
(Janowski et al., 1996). The two LXR isotypes share considerable
sequence homology and respond to the same ligands, but their
tissue distribution differs markedly. LXRa is highly expressed in
liver, adipose tissue, and macrophages, and LXRb is expressed
ubiquitously (Repa and Mangelsdorf, 2000). Many LXR target
genes are involved in cholesterol and fatty acid metabolism,
such as ABCA1, ABCG1, SREBP-1c, and fatty acid synthase
(Tontonoz and Mangelsdorf, 2003). Other targets, such as AIM/
SPa, are involved in the regulation of apoptosis and innate
immune responses (Joseph et al., 2004; Valledor et al., 2004).Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 97
LXRs also have the capacity to negatively regulate inflamma-
tory gene expression via transrepression (Joseph et al., 2003).
The LXR pathway has been shown to impact inflammatory res-
ponses in models of atherosclerosis, contact dermatitis, sepsis,
andmultiple sclerosis (Hindinger et al., 2006; Joseph et al., 2003;
Joseph et al., 2002; Tangirala et al., 2002). Although the mecha-
nisms underlying signal-specific transrepression remain incom-
pletely understood, it is clear that activation of LXR inhibits in-
flammatory responses to LPS or cytokines in part via blockade
of NF-kB signaling (Joseph et al., 2003; Ogawa et al., 2005).
Recent studies have suggested that LXR-dependent repression
of inflammatory target genes occurs via an N-CoR- and sumoy-
lation-dependent process (Ghisletti et al., 2007). Interestingly,
activation of TLR3 or TLR4 inhibits LXR cholesterol function via
the transcription factor IRF-3, suggesting that LXR functions to
regulate the crosstalk between inflammatory and metabolic
pathways (Castrillo et al., 2003). Despite recent progress in
understanding of the links between LXR and innate immunity,
little is known regarding the impact of LXR signaling on T and
B cell biology and acquired immunity.
We demonstrate here that transcriptional regulation of intra-
cellular cholesterol homeostasis impacts cell proliferation and
acquired immune responses. We show that T cell activation is
accompanied by the downregulation of LXR target genes
involved in cholesterol transport and the simultaneous induction
of the SREBP-2 pathway for cholesterol synthesis. Ligand acti-
vation of LXR inhibits mitogen-driven T cell expansion by altering
cellular sterol content through a pathway requiring the trans-
porter ABCG1. Conversely, loss of LXR expression confers a
proliferative advantage to lymphocytes, resulting in enhanced
homeostatic and antigen-driven responses. LXR-dependent
coupling of cholesterol metabolism and proliferation represents
a previously unrecognized mechanism for the regulation of
immune responses.
RESULTS
Age-Dependent Lymphoid Hyperplasia in Mice Lacking
LXRb Expression
To investigate the role of LXRs in lymphoid cells, we examined
the immune system of young Lxra and Lxrb null mice (Peet
et al., 1998) on a C57BL/6 background (greater than ten genera-
tions backcrossed). Flow cytometric analysis of spleen, lymph
node (LN), and thymus from 6- to 8-week-old Lxra and Lxrb
null mice revealed no significant differences in the frequency of
CD4+ and CD8+ T and CD19+B220+ B lymphocyte populations
when compared to LXR-sufficient controls (Figure S1A available
online and data not shown). Thus, global loss of either LXR
isotype does not grossly alter the development of T or B lympho-
cytes. However, analysis of hematopoetic tissues from older
Lxrb null mice (5–6 months) revealed moderate splenomegaly
and an expansion in the total number of lymphocytes in spleen
(p = 0.01) and LN (p = 0.01) (Figures 1A and 1B). No significant
difference in the frequency of T and B cells was noted in the
spleen, whereas LNs from Lxrb null mice consistently showed
a modest expansion in the B cell compartment (Figure 1C).
Since Foxp3+ Regulatory T cells (Tregs) play an important role
in maintaining lymphocyte homeostasis, we considered the98 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.possibility that the lymphoid hyperplasia might reflect a loss of
Tregs. However, FACS analysis of Lxrb null spleen and LN cells
revealed no difference in the frequency of CD4+Foxp3+ T cells
(Figure S1B), nor were differences noted in the activation
markers CD69, CD25, and CD44 (Figure S1C; data not shown).
Similarly, no differences were observed in the frequency of den-
dritic cells (DCs) from spleens of Lxrb null mice or inMHC class II,
CD86, and CD40 expression levels. These observations suggest
that antigen-presenting cells are not activated and are not
directly mediating the lymphoid hyperplasia (Figure S2).
Next, we examined the expression pattern of Lxra and Lxrb in
murine immune cells. Lxra was expressed at high levels in peri-
toneal-derived macrophages and bone-marrow-derived macro-
phages, whereas little or no mRNA was detected in resting
purified B and T cells (Figure S3A). Lxrb was expressed in mac-
rophages, T cells, and B cells. We considered the possibility that
activation of lymphocytes might alter Lxra expression, but we
failed to detect expression in splenic T cells from C57BL/6
mice activated with plate-bound anti-CD33 (pbCD3) mAb in the
presence or absence of 2 mM GW3965 (synthetic LXR agonist;
Figure S3B). Human T cells were also found to express LXRb
but not LXRa protein (Figure S3C). As expected, expression of
LXRa in THP-1 macrophages was induced by GW3965 as a
result of autoregulation (Laffitte et al., 2001) (Figure S3C). Activa-
tion of LXR induced target gene expression in human T cells but
did not lead to the upregulation of LXRamRNA (Figure S3D; data
not shown).
LXRb Is an Intrinsic Regulator of Lymphocyte
Proliferation
We hypothesized that LXR may regulate proliferation and/or
acquisition of effector functions in lymphocytes. To test this pos-
sibility, we examined 3H-thymidine incorporation into whole
spleen cells from WT, Lxra null, or Lxrb null mice stimulated
with a panel of mitogenic stimuli. Interestingly, anti-IgM-
(Fab’)2-, concavalin A- and PMA/ionomycin-stimulated spleen
cells from Lxrb null mice incorporated significantly more thymi-
dine than did those from WT controls (Figure 1D; data not
shown). So that it could be determined whether this effect was
due to an intrinsic difference in cell proliferation, purified CFSE-
labeled T cells were stimulated with pbCD3 and analyzed by
flow cytometry for proliferative response and viability. No differ-
encewas observed in cell viability or the dilution of CFSE-labeled
T cells at 24 hr, indicating that Lxrb null T cells do not have an in-
herent early survival advantage (Figure 1E). However, analysis at
72 hr and 96 hr revealed that the absolute number of T cells that
had divided in response to TCR stimulus wasmarkedly greater in
Lxrb null T cells than in Lxra null and WT cells (Figure 1F). Thus,
LXRb expression intrinsically regulates lymphocyte expansion in
response to either TCR, BCR, or pharmacologic activation.
LigandActivation of LXR Inhibits Lymphocyte Expansion
In complimentary studies, we asked whether LXR activation
altered the proliferative capacity of lymphocytes in vitro. Spleen
cultures from C57BL/6 mice were stimulated with anti-IgM-
(Fab’)2 or pbCD3 in the presence or absence of GW3965, LG68
(RXR agonist), or a physiologic LXR ligand, 22(R)-hydroxycholes-
terol. After 48–96 hr, cultures were pulsed with 3H-thymidine
Figure 1. Splenomegaly and Lymphocyte Expansion in Mice Lacking LXRb
(A) Total cellularity of spleen and LN from 6-month-old WT and LXRb KO mice.
(B) Gross morphology of spleens.
(C) Frequency of CD4 and CD8 T cells from spleen and LN.
(D)Mitogen-driven proliferation of spleen cells from6- to 8-week-oldWT, LXRaKO, or LXRbKOmice.Cellswere stimulatedwith anti-IgM(Fab’)2 (10 mg/mL), ConA
(10 mg/mL), or PMA (0.5 mM) and ionomycin (100 mM). 3H-thymidine was added to cultures after 72 hr for the final 16 hr. *p < 0.01; **p < 0.001.
(E and F) TCR-driven proliferation of spleen cells fromWT, LXRaKO, or LXRbKOmice. PurifiedCFSE-labeled T cells were stimulatedwith pbCD3 (10 mg/mL). Cells
were harvested at 24 hr (E) and 72 hr (F), stained with anti-CD4, CD8, and 7-AAD. Counting beads (53 104) were added to samples to serve as an internal control.
Error bars represent ± SEM.overnight so that proliferation could be determined. Activation of
LXR by LXR and/or RXR agonists markedly reduced the prolifer-
ative capacity of cultured cells (Figure 2A). Similarly, proliferation
of B and T cells was inhibited by 22(R)-hydroxycholesterol in
a dose-dependent manner.
To determine whether the inhibitory effect of LXR agonists on
lymphocyte proliferation was receptor dependent, cultures were
stimulated with a panel of T and B cell mitogens in the presence
or absence of receptor agonists. Activation of LXR alone or in
combination with RXR markedly reduced 3H-thymidine incorpo-
ration in WT spleen cell cultures stimulated with Con A, anti-IgM,
or LPS (Figure 2B and Figure S4). A similar reduction in 3H-thymi-dine incorporation was seen in spleen cells from Lxra null mice.
In contrast, LXR activation had little or no effect on 3H-thymidine
incorporation into mitogen-stimulated Lxrb null splenocytes
(Figure 2B and Figure S4). A modest decrease in 3H-thymidine
incorporation was observed in LG268-treated splenocytes stim-
ulated with LPS and anti-IgM, indicative of an RXR-dependent,
LXR-independent effect in B cells (Figure 2B and Figure S4).
However, this decrease was not observed in Con A-treated
spleen cells, suggesting that RXR activation alone does not
perturb T cell expansion in this system (Figure 2B).
We considered the possibility that activation of LXR in whole
spleen cultures might indirectly impact lymphocyte expansionCell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 99
Figure 2. LXR Activation Inhibits Lymphocyte Proliferation
(A) Decreased mitogen-driven proliferation of WT spleen cells stimulated with anti-IgM(Fab’)2 (10 mg/mL) or pbCD3 (10 mg/mL) and LXR ligands GW3965
(2 mM), 22(R)-hydroxycholesterol (0.156 mM-2.5 mM), or RXR ligand LG268 (100 nM) as indicated. 3H-thymidine was added to cultures after 72 hr for the
final 16 hr.
(B) WT, LXRa KO, or LXRb KO splenocytes were stimulated with ConA (10 mg/mL) or LPS (100 mg/mL) and treated with LXR ligands GW3965 (2 mM), T1317
(1 mM), and RXR ligand LG268 (100 nM) as indicated. 3H-thymidine was added to cultures after 72 hr for the final 16 hr.
(C and D) CFSE dilution and viability of purifiedWT, LXRa KO, or LXRb KO T cells stimulated with pbCD3 in the presence of GW3965 and LG268 was determined
at 24–96 hr.100 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.
through actions on other cell types. So that this issue could be
addressed, purified T cells were CFSE labeled and stimulated
with pbCD3 in the presence of either receptor agonists or vehi-
cle. Importantly, therewas no significant difference in the viability
of T cells cultured with LXR/RXR ligands at 24 hr, indicating that
they are not inherently toxic to lymphocytes at these concentra-
tions (Figure 2C). FACS analysis of cultures at 48–96 hr revealed
that LXR activation inhibited proliferation of WT and Lxra null T
cells, but not Lxrb null cells (Figure 2D). Thus, LXR activation
has an intrinsic effect on lymphocyte proliferation that is medi-
ated by LXRb. We have also observed LXR-dependent inhibition
of proliferation in developing bone-marrow-derived monocytes
cultured with M-CSF in vitro (data not shown). Interestingly, we
failed to observe an effect of LXR ligands on the proliferation of
a number of transformed T and B cell lines (including Jurkat
and Ramos; data not shown). This observation suggests that
many transformed cells have lost their sensitivity to the LXR
antiproliferative effect.
Efficient T cell activation requires two signals. The first is me-
diated via the TCR, whereas the second can be transmitted from
a number of cell-surface receptors (Bromley et al., 2001). To de-
termine whether costimulation could restore proliferation in the
presence of ligand, we activated purified WT T cells with
pbCD3 and added either soluble anti-CD28 or rIL-2. As ex-
pected, LXR activation markedly reduced proliferation in re-
sponse to pbCD3 (Figure 2E); however, the addition of anti-
CD28 or IL-2 to cultures did not rescue.
Next, we investigated whether the effects of LXR on lympho-
cyte expansion were also shared with other members of the
nuclear receptor superfamily. In addition to LXR, both PPARg
and GR are known to inhibit inflammatory responses in im-
mune cells (Ogawa et al., 2005). Treatment of T cells with
dexamethasone caused cell death in 75%–90% of cells after
24 hr, whereas activation of LXR, RXR, or PPARg had little ef-
fect (Figure 2F and Figure S5C). Interestingly, in contrast to
LXR activation, PPARg signaling conferred a modest survival
advantage to proliferating T cells in vitro at later time points
(data not shown). Thus, LXRb activation regulates lymphocyte
expansion in a manner distinct from glucocorticoid receptor
and PPARg.
For the determination of whether the transcriptional program
initiated by LXR also regulates human lymphocytes, purified
T cells were collected from peripheral blood of normal donors.
Purified T cells were treated with vehicle or receptor ligands
and stimulated with pbCD3 +/ soluble anti-CD28. In contrast
to what is seen in murine lymphocytes, LXR/RXR activation
did not induce apoptosis in cultures analyzed up to 72 hr
(Figure S5D). Similar to murine lymphocytes, LXR activation
also decreased the proliferative capacity of human CD8+ or
CD4+ T cells stimulated with pbCD3 (Figure 2G and
Figure S5A). In contrast to murine T cells, the addition of anti-
CD28 was able to overcome the LXR-mediated inhibition ofproliferation (Figure S5B), suggesting subtle differences in the
biology of LXR in mouse and human lymphocytes.
LXR Activation Blocks Cell-Cycle Progression
in Lymphocytes
One possible explanation for the antiproliferative effects of LXR
is that the receptor is engaging an apoptotic pathway that de-
creases the total number of lymphocytes proliferating. Alterna-
tively, it could be that LXR-dependent transcription is regulating
cell-cycle progression. Analysis of forward scatter (FSC) and
side scatter (SSC) characteristics of cultured T cells demon-
strated that neither the activation nor ablation of LXR altered cel-
lular enlargement in response to pbCD3 (Figure 3A; data not
shown). However, examination of T cell blasts at 36–48 hr clearly
established that LXR-activated cells did not divide efficiently
(Figure 3B). Transgenic overexpression of the antiapoptotic
factor Bcl-xL or addition of the caspase inhibitor ZVAD-fmk
provided amodest survival advantage over their wild-type coun-
terparts but did not restore proliferation in the presence of LXR
ligand (Figure 3C; data not shown), consistent with a primary
effect of LXR on proliferation rather than cell viability.
Next, we analyzed the DNA content of activated T cells in the
presence or absence of LXR ligand. Interestingly, Lxrb null T cells
displayed an increased fraction of cells in S and G2/M phase and
a decreased sub2N fraction at 36–48 hr compared to WT cells
(Figure 3D and Figure S6). WT but not Lxrb null cells treated
with LXR agonist showed a markedly reduced fraction of cells
moving through the cell cycle and an increase in the apoptotic
sub2N fraction (Figure 3D and Figure S6). Analysis of DNA con-
tent in pbCD3-stimulated human T cell cultures also indicated
a significant reduction in cells entering S phase at 24 hr with
no difference in the sub2N fraction (data not shown). Thus, acti-
vation of LXRb limits the capacity of T cells to move through the
cell cycle, resulting in decreased proliferation.
We also analyzed the expression of cell-cycle proteins. qPCR
analysis of GW3965-treated lymphocytes showed normal
upregulation of cylin D2, D3, and c-Myc, suggesting movement
into G1 (data not shown). Similarly, we observed normal upregu-
lation of proliferation-associated antigen Ki-67 and CDK 4
(Figures 3E and 3F). However, ligand-treated cells maintained
increased levels of the cell-cycle inhibitor p27kip, indicating a de-
creased ability to move through cell cycle. Accordingly, viable
ligand-treated cells showed decreased PCNA expression at
48 hr (Figure 3E). We also observed decreased mRNA expres-
sion of cyclin E1 and E2 (data not shown), further supporting
our assertion that enforced LXR activation decreases cell-cycle
progression in activated lymphocytes.
LXR Signaling Does Not Inhibit Lymphocyte Activation
The NF-kB signaling pathway plays an important role in lympho-
cyte activation (Schulze-Luehrmann and Ghosh, 2006). Since
LXR is known to block NF-kB-dependent gene expression, we(E) CFSE dilution of purified WT T cells at 72 hr stimulated with pbCD3, soluble CD28, rIL-2, and/or LXR/RXR agonist as indicated.
(F) Annexin and PI staining of pbCD3 stimulated WT T cells cultured with GW3965 and LG268.
(G) CFSE dilution of human T cells stimulated with anti-CD3 crosslinked with pb goat anti-mouse and cultured with GW3965 or T1317. Counting beads (53 104)
were added to samples (C, D, E, and G) to serve as an internal counting control and analyzed via flow cytometry.
Error bars represent ± SEM.Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 101
Figure 3. LXRb Signaling Regulates Cell-Cycle Progression
(A–C) CFSE dilution of WT and Bcl-xL tg T cells stimulated with pbCD3 (10 mg/mL) for 36–96 hr in the presence of GW3965 (2 mM) and LG268 (100 nM). Cells were
stained with 7-AAD and analyzed by flow cytometry.
(D) Cell-cycle analysis of WT and LXRb KO T cells stimulated with pbCD3 and GW3965 and LG268 as indicated. Cells were stained for DNA content with propi-
dium iodide at 48 hr and analyzed by flow cytometry.
(E and F) Cell-cycle proteins of WT T cells stimulated with pbCD3, GW3965, and LG268 as indicated. (E). Cells were permeabilized and stained for intracellular
proliferation antigens Ki-67, PCNA and topro-3 for DNA content at 36 hr. Whole-cell lysates were collected and analyzed by western blot for p27kip and CDK4
expression at 18 hr (F).considered the possibility that the anti-inflammatory action of
LXR might underlie its effects on lymphocyte expansion. How-
ever, LXR activation did not significantly impact the upregulation
of the activation markers CD69 and CD25 at 24 hr (Figure S7A;
data not shown). LXR/RXR activation also did not perturb IL-2
production (Figure S7B). Furthermore, restimulation of resting
T cells with IL-2 led to comparable induction of the IL-2-respon-
sive genes lymphotoxin A and granzyme B (Figure S7C)
(Beadling and Smith, 2002; Kovanen et al., 2005). Coupled
with the observations that Lxrb null T cells do not express higher
levels of CD25, CD44, or CD69 ex vivo (Figure S1D and data not102 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.shown) and do not upregulate these markers to a greater extent
in response to TCR crosslinking (Figure S7D), these data strongly
suggest that the regulation of proliferation by LXR is not achieved
through alterations of TCR or IL-2 signaling or inhibition of
proximal lymphocyte activation.
We also addressed when LXR activation must occur in relation
to TCR signals in order to block proliferation. To that end, CFSE-
labeled T cells were activated with pbCD3 for 24 hr before LXR/
RXR ligands were added to cultures. Interestingly, activation of
LXR after 24 hr of TCR signaling perturbed expansion only in later
rounds of division (Figure S8). If LXR ligands were washed out
2 hr after stimulation, then proliferation was restored (Figure S8),
indicating that sustained LXR signaling is required to inhibit
proliferation. These observations suggested that the effects of
LXR were likely to be mediated by activation or repression of
downstream target genes (see below).
Reciprocal Regulation of the SREBP-2 and LXR
Transcriptional Programs during Lymphocyte Activation
To determine the mechanism by which LXR modulates prolifer-
ation, we profiled gene expression in splenic murine T lympho-
cytes before or after stimulation with pbCD3 in the presence or
absence of LXR agonists. In particular, we examined genes
involved in de novo cholesterol biosynthesis, reverse cholesterol
transport, and cholesterol uptake. Consistent with previous
reports showing that cholesterol synthesis is stimulated in acti-
vated T cells (Chen et al., 1975), our findings indicate that the en-
tire pathway of SREBP-2 target genes was induced after activa-
tion (Figure 4A). Pathways for fatty acid and phospholipid
synthesis were also induced, consistent with activation of
SREBP-1 (data not shown). Unexpectedly, TCR activation also
resulted in the concomitant and profound downregulation of
LXR target genes, including two key genes involved in choles-
terol transport, Abca1 and Abcg1 (Figure 4A). In contrast, cultur-
ing of activated lymphocytes with LXR led to a robust induction
of these genes. The transcriptional effects of LXR were notably
more limited in T cells as compared to other cell types, such
as macrophages. A relatively small number of genes were
altered by LXR activation, and the vast majority were linked to
cholesterol metabolism. In fact, many LXR target genes
expressed in other cell types (e.g., apoE, PLTP, apoD, ABCG5,
ABCG8) are absent in T cells (data not shown). We also noted
that culturing activated lymphocytes with LXR agonist modestly
promoted SREBP-2 target gene expression (Figure 4A). This
effect may be secondary to increased SREBP-1 expression
driven by LXR or may reflect alterations in cholesterol content
in the endoplasmic reticulum (ER) (see below).
Analysis of LXR and SREBP-1 target gene expression by real-
time PCR confirmed that T cell activation is accompanied by the
rapid and reciprocal regulation of these transcriptional path-
ways. For example, Abca1 and Abcg1 expression begins to
decline, whereas Ldlr and Hmcgr expression begins to increase
as early as 2 hr after activation (Figure 4B). The regulation of
Abca1 and Abcg1 during T cell activation is LXR dependent,
because deletion of LXRb in T cells abolished both basal and li-
gand-inducible target gene expression (Figure 4C). To determine
whether LXR target genes were also downregulated during lym-
phocyte activation in vivo, C57Bl/6 mice were injected intraper-
itoneally (i.p.) with anti-CD33 antibody. Spleens were harvested
12 hr after injection, and mRNA was collected from purified
T cells. In line with our in vitro observations, the LXR target genes
Abca1, Abcg1, and Srebp-1c were markedly suppressed upon
activation, whereas Lxrb expression was maintained (Figure 4D).
Reciprocal regulation of the LXR andSREBP pathways by pro-
liferative stimuli was also observed in primary murine B cells
activated via the BCR and with PMA/ionomycin (Figure 4E;
data not shown). A similar reciprocal relationship between LXR
and SREBP target genes was observed in human lymphocytes
activated with PMA/ionomycin (Figure S9). We also examinedC57BL/6 mouse embryonic fibroblasts (MEFs) under basal con-
ditions, serum starvation (G1 arrest), and refeeding (re-entry in to
cell cycle). Real-time PCR confirmed that proliferative stimuli
trigger suppression of LXR targets and induction of SREBP-2
targets in MEFs. Interestingly, serum deprivation for 24 hr upre-
gulated LXR target gene expression inMEFs (Figure 4F). Release
from cell-cycle arrest via refeeding for 6 hr with serum upregu-
lated the SREBP-2 target genes Ldlr and 17b-Hsd and downre-
gulated expression of LXR target genes. These data mirror the
gene expression patterns observed in quiescent and activated
lymphocytes, suggesting that the reciprocal regulation of LXR
and SREBP-2 activity is a general feature of cells moving through
early stages of the cell cycle.
Proliferative Stimuli Induce SULT2B1 Expression
and Reduce LXR Ligand Availability
The loss of LXR target gene expression despite preserved
expression of the receptor strongly suggests that the abundance
of endogenous LXR ligand is reduced during T cell activation.
Consistent with this hypothesis, culturing primary T cells in the
presence of the HMG-CoA reductase inhibitor simvastatin, pre-
viously shown to block production of LXR agonists, led to a
reduction inAbca1 andAbcg1 expression (Figure 5A). Moreover,
the addition of mevalonic acid restored their expression, indicat-
ing that oxysterol production from the mevalonate pathway is
required for the maintenance of LXR activity in quiescent lym-
phocytes. Finally, target gene expression was also restored by
the direct addition of the endogenous LXR agonist 22(R)-HC
(data not shown).
To investigate the potential mechanism for regulation of LXR
ligand availability during T cell activation, we returned to our tran-
scriptional profiling analysis. Remarkably, expression of the oxy-
sterol-metabolizing enzyme SULT2B1 was rapidly induced in
response to T cell activation. SULT2B1 catalyzes the transfer
of sulfate groups to oxysterols, inactivating them as LXR ligands
and facilitating their export from the cell by ABCC1 and other
membrane transporters (Chen et al., 2007; Javitt et al., 2001;
Zelcer et al., 2003). Real-time PCR revealed that both SULT2B1
and ABCC1 were rapidly induced by proliferative stimuli (pbCD3
or PMA/ionomycin) in T cells (Figure 5B; data not shown). Impor-
tantly, a pronounced upregulation of SULT2B1 was also ob-
served in T cells activated in vivo (Figure 5C). This observation
strongly suggests that LXR target gene expression is sup-
pressed during T cell activation through activemetabolism of en-
dogenous oxysterol LXR agonists. In support of this hypothesis,
adenoviral expression of SULT2B1 in resting primary T cells from
adenoviral receptor-expressing transgenic mice (Wan et al.,
2000) recapitulated the effects of proliferative stimuli on both
LXR and SREBP-2 target gene expression (Figure 5D).
LXR Inhibits Proliferation through ABCG1-Dependent
Alteration of Cholesterol Homeostasis
The observation that T cell activation is associated with a reduc-
tion in endogenous LXR activators, coupled with the prominent
regulation of LXR-dependent sterol transporters, suggested
LXR may modulate T cell proliferation through control of choles-
terol metabolism. We ruled out the possibility that limiting
extracellular cholesterol availability was involved in the effectsCell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 103
Figure 4. Reciprocal Regulation of the LXR and SREBP-2 Transcriptional Programs during Lymphocyte Activation
(A) DNA microarray analysis of SREBP-2 and LXR target genes of purified WT T cells stimulated with pbCD3 and GW3965 (2 mM).
(B) Real-time PCR analysis of mRNA from purified WT T cells stimulated with pbCD3 (10 mg/mL) for the indicated time.
(C) Real-time PCR analysis of mRNA from purified WT and LXRb KO T cells stimulated for 24 hr with pbCD3 and GW3965 as indicated.
(D) Real-time PCR analysis of LXR and LXR target genes from mRNA of purified WT T cells of mice treated with 20 mg anti-CD3e i.p. for 12 hr.
(E) Real-time PCR analysis of mRNA from purified WT B cells stimulated for 4 hr with anti-IgM and GW3965 as indicated.
(F) Real-time PCR analysis of mRNA from proliferating (basal), serum-starved (starved), and refed WT mouse embryonic fibroblasts.
Error bars represent ± SEM.of LXR agonist on T cell proliferation by supplementing cultures
with excess LDL. Addition of as much as 100 mg protein/ml LDL
had no effect on cell proliferation in the presence or absence of
LXR agonist (Figure 6A; data not shown). We next addressed the104 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.possibility that LXR-dependent alteration of intracellular choles-
terol metabolism was linked to proliferation. Assessment of
global membrane cholesterol content by fillipin staining showed
increased total cholesterol content in blasting T cells but no
gross difference between vehicle and LXR agonist treatment
(Figure 6B). However, intracellular cholesterol trafficking is com-
plex, and intracellular pools are not necessarily in equilibrium
with the plasma membrane (Chang et al., 2006; Simons and
Ikonen, 2000). Therefore, this crude analysis does not rule out
more subtle or compartment-specific changes in sterol levels
or changes in the abundance of rare sterol species [such as
oxysterols; (Yancey et al., 2003)].
Previous work has established that ABCG1 and ABCA1 play
central roles in both LXR-dependent sterol efflux and intracellu-
lar sterol trafficking. We therefore tested the requirement for
these transporters in the antiproliferative effects of LXR agonists.
Purified WT and Abcg1 null lymphocytes were activated with
PMA/ionomycin in the presence or absence of GW3965 and/or
LG268. After 48–96 hr, CFSE proliferation profiles were assessed
by flow cytometry. As expected, LXR agonist reduced the prolif-
erative capacity of WT T cells (Figure 6C and Figure S11). Re-
markably, however, the effects of LXR activation were greatly
attenuated in cells lacking ABCG1. We also analyzed effects of
LXR agonists on ABCA1 null and background-matched (B6/
129) ABCA1+/+ controls. Unfortunately, the ABCA1 null mutation
is lethal in the C57BL/6 background, precluding a direct compar-
ison of ABCG1 and ABCA1 on the same background. Neverthe-
less, loss of ABCA1 expression did not alter the response to LXR
agonist (Figure 6D), suggesting that this transporter is not
required for the LXR effect.
The above observations indicate that transport of sterols by
ABCG1 is required for LXR agonists to inhibit cell proliferation.
Figure 5. Regulation of LXR Signaling by
SULT2b1 during T Cell Activation
(A) Real-time PCR analysis of LXRb and ABCG1
from quiescent WT T cells cultured with simvasta-
tin and 5 mM mevalonic acid.
(B) Real-time PCR analysis of SULT2b1, ABCC1,
LDLR, and ABCG1 mRNA from purified WT T cells
stimulated with anti-CD3 in vitro for the indicated
times.
(C) Real-time PCR analysis of SULT2b1and
ABCG1 mRNA from purified WT T cells stimulated
for 12 hr with anti-CD3 in vivo.
(D) Real-time PCR analysis of LXRb, LDLR, and
ABCA1 mRNA from CAR-tg T cells transduced
with SULT2b1-containing or control adenovirus.
Error bars represent ± SEM.
In strong support of this mechanism, the
inhibitory effect of LXR activation could
be completely overcome by providing
lymphocytes with an excess of mevalo-
nate (5 mM), the precursor for cholesterol
and oxysterols (Figure 6E). Importantly,
providing cells with levels of mevalonate
sufficient to allow nonsteroidal modifica-
tions, such as protein prenylation, but in-
sufficient to drive sterol synthesis (100
mM) had no effect on LXR-dependent in-
hibition. These data identify ABCG1 as
a key component of a sterol trafficking
pathway that must be downregulated during T cell activation.
Enforced expression of ABCG1 during T cell activation by exog-
enous LXR agonists engages ametabolic checkpoint that blocks
proliferation through alteration of intracellular sterol metabolism.
Endogenous LXR Signaling Regulates Acquired
Immune Responses
To definitively determine whether the intrinsic loss of LXRb sig-
naling in T cells would translate into a proliferative advantage
in vivo, we used a competitive adoptive transfer model of ho-
meostatic proliferation. For these studies, 1 3 106 Lxrb null
(Thy1.2+) T cells and an equivalent number of congenic WT
(Thy1.1+) T cells were coadoptively transferred into the same
B6.RAG null host and allowed to undergo homeostatic prolifera-
tion for 1 week. Strikingly, FACS analysis of spleen and blood
from host animals revealed that the frequency of Lxrb null
(Thy1.1, CD3+) T cells was much higher (p = 0.003) than that
of WT (Thy1.1+, CD3+) T cells isolated from the same host
(Figure 7A).
In complimentary studies, we asked whether the activation of
LXR would prevent the expansion of WT T cells in vivo. To that
end, we pretreated purified WT Thy1.2+ T cells and WT
Thy1.1+ T cells with GW3965 or vehicle, respectively, for 18 hr
in vitro to allow for initiation of the LXR transcriptional program.
Live cells were collected, and 1 3 106 vehicle- (Thy1.1+) and
GW3965- (Thy1.2+) treated cells were injected into B6.RAG null
mice. Peripheral blood and spleen were subsequently analyzed
for Thy1.1+ and Thy1.2+CD3+ T cells on days 5–7. ConsistentCell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 105
Figure 6. LXR Inhibits Proliferation through Abcg1-Dependent Alteration of Cholesterol Homeostasis
(A) CFSE dilution of WT T cells stimulated with pbCD3 and GW3965 in the presence of 10 mg/mL LDL for 60 hr.
(B) Cholesterol content of plasma membrane fromWT T cells revealed by fillipin staining ex vivo or after 24 hr stimulation with pbCD3 and GW3965 as indicated.
(C and D) CFSE dilution of purified abcg1/, abca1/, and control T cells stimulated with PMA and ionomycin in the presence of LXR ligands for 60 hr.
(E) CFSE dilution of purified WT T cells stimulated with pbCD3 for 96 hr in the presence of GW3965 and mevalonic acid (MVA) as indicated.with the above loss-of-function studies, pretreatment of T cells
with LXR ligand markedly reduced the frequency of T cells
undergoing homeostatic proliferation (Figure 7B).
The ability of LXR to modulate lymphocyte expansion strongly
suggested that endogenous LXR signaling might have a func-
tional impact on acquired immune responses. To determine
whether loss of LXRbwould augment antigen driven proliferation
in vivo, we immunized mice with 1 3 107 TAP-deficient mouse
embryo cells (MECs) expressing the human adenovirus type 5
early region 1 (Ad5E1). Antigen-specific CD8+ T cells were enu-
merated ex vivo 1 week after immunization by intracellular IFN-g
and TNF-a staining after a short-term in vitro restimulation with
the E1B antigen E1B192-200 (VNIRNCCYI) (Toes et al., 1998). Re-
markably, FACS analysis indicated that the frequency of antigen-
specific Lxrb null IFN-g+ (p = 0.02) or TNF-a+ (p = 0.01) CD8+ T
cells was 2- to 3-fold higher than that of their WT counterparts
(Figures 7C and 7D). Thus, antigen-driven expansion of CD8+ T
cells is negatively regulated by LXRb inWTmice. Taken together,106 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.these data establish LXR-dependent sterol metabolism as a
novel signaling pathway regulating T cell function and immune
responses.
DISCUSSION
An important characteristic of adaptive immunity is the capacity
of antigen-specific lymphocytes to undergo rapid and extensive
proliferation in response to antigenic challenge. Thus, under-
standing the signaling pathways that impact proliferation is crit-
ical to understanding how immune responses are generated and
controlled. Previous work from a number of laboratories has out-
lined the importance of glycolytic metabolism in T cell responses
(MacDonald and Cerottini, 1979; Rathmell et al., 2000; Vander
Heiden et al., 2001). The influence of lipid metabolism on lym-
phocyte function, however, is poorly understood. We have
shown here that intracellular sterol metabolism has a previously
unrecognized regulatory role in the control of acquired immune
Figure 7. LXR Signaling Regulates T Cell Proliferation and Immunity
(A) Homeostatic proliferation of WT and LXRb KO T cells. One million purified WT (Thy1.1+) and LXRb KO T cells (Thy1.2+) were coadoptively transferred into
B6Rag/ hosts. After 5 days, spleens were harvested and cells stained with anti-CD3 and Thy1.1 to determine the frequency of recovered T cells. Each
FACS plot represents an individual mouse, and the graph represents five mice from one experiment.
(B) Homeostatic proliferation ofWT T cells stimulated with LXR/RXR ligands.WT (Thy1.2+) T cells were pretreatedwith GW3965 in vitro for 18 hr. Control (Thy1.1+)
T cells were pretreated with DMSO in vitro for 18 hr. One million live cells per treatment group were coadoptively transferred into B6Rag/ hosts. After 5 days,
spleens were harvested and cells stained with anti-CD3, Thy1.1, and Thy1.2. Each FACS plot represents an individual mouse of five mice from one experiment.
(C and D) Increased antigen-specific immune response in LXRb KO mice. WT and in LXRb KO mice were immunized with 1 3 107 syngeneic MECs transfected
with the human adenovirus type 5 early region 1 (Ad5e1). The frequency of antigen-specific CD8+ T cells in whole spleen was enumerated ex vivo 1 week after
immunization by intracellular IFN-g and TNF-a staining after a short-term in vitro restimulation with the E1B192-200 (VNIRNCCYI) peptide (C). FACS data presented
is two mice per genotype representative of four mice per group. The frequency of antigen-specific IFN-g- and TNF-a-producing CD8 T cells within the CD8 T cell
compartment is shown (D). Data is presented as the mean ± SEM of four mice per group. Each experiment was repeated twice.
Error bars represent ± SEM.responses. Cholesterol is an essential component of mem-
branes and therefore the requirement for adequate cholesterol
in cell reproduction is obvious. However, our data reveal that
the intracellular availability of sterols is dynamically regulated
during T cell activation and that this is linked to transcriptional re-
sponses mediated by SREBP and LXR, as well as to cell-cycle
control. Moreover, we show that the ability of LXR to alter cellular
sterol metabolism through regulation of the ABCG1 sterol trans-
porter impacts both lymphocyte proliferation and antigen-stimu-
lated immune responses.
The initial clue to a potential role for LXR signaling in innate im-
mune cells came from analysis of LXR null mice, which exhibit
age-dependent splenomegaly and lymphadenopathy. This phe-notype reflects expansion in both the T and B cell compartments
and is linked to the previously unrecognized ability of LXRb to
regulate mitogen- and antigen-driven lymphocyte proliferation.
Analysis of purified primary lymphoid cultures established that
activation of LXRb by physiologic or pharmacologic ligands di-
minishes the proliferative capacity of B and T cells. Conversely,
genetic loss of LXRb rescues cells from the inhibitory effect of
LXR agonist and potentiates mitogen- and antigen-driven ex-
pansion. We also demonstrated that the ability of LXR to impact
cell proliferation has a functional consequence for lymphoid
homeostasis and antigen-driven immune responses in vivo.
Lymphocytes lacking LXRb expression show an exaggerated
response in both homeostatic and vaccine-driven proliferationCell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc. 107
models. Thus, endogenous LXR signaling is a physiologically im-
portant determinant of immune responses, and pharmacological
LXR activation has the potential for immune modulation.
Given the ability of LXR to inhibit NF-kB signaling in macro-
phages, we initially suspected that LXR might interfere with
TCR signaling and proximal pathways involved in lymphocyte
activation. However, this appears not to be the case because
markers of activation and IL-2 production were not affected by
LXR ligands.We also excluded the possibility that LXR activation
was causing apoptosis directly, as is known to occur with GR
agonists. Rather, cell-cycle analysis indicated that LXR signaling
was regulating the G1-to-S transition. Collectively, these obser-
vations suggested that LXR was controlling the expression of
one or more genes whose action was inhibitory to cell-cycle pro-
gression. To identify such genes, we profiled gene expression
during lymphocyte activation. We found that a battery of genes
linked to cholesterol homeostasis is dynamically regulated dur-
ing lymphocyte activation and that exogenous LXR ligand alters
this metabolic program. In particular, the genes encoding the
sterol transporters ABCA1 and ABCG1—both LXR targets—
are rapidly downregulated upon T cell receptor crosslinking.
The addition of LXR agonist strongly stimulates their expression.
These findings led to the hypothesis that ABCG1 action alters
sterol metabolism in lymphocytes in a manner that is inhibitory
to proliferation. Definitive support for the requirement of
ABCG1 in this model is provided by the demonstration that the
ability of LXR to inhibit proliferation is markedly reduced in lym-
phocytes from Abcg1 null mice. A definitive link to sterol metab-
olism is established by the observation that the inhibitory effect
of LXR is completely blocked if lymphocytes are provided with
an excess of mevalonate, the precursor for cholesterol and
oxysterols.
Our results reveal the existence of an endogenous sterol sig-
naling pathway that regulates lymphocyte proliferation through
coordinate regulation of SREBP and LXR activity. The changes
in SREBP and LXR target gene expression we observe during
T cell activation are indicative of alterations in endogenous sterol
regulators of both transcription factors. Brown and Goldstein
have delineated an elegant mechanism for the regulation of cho-
lesterol synthesis in which SREBP is held as an inactive precur-
sor in the ER by the sterol-sensing protein SCAP (Goldstein et al.,
2006). A logical conclusion of our data is that sterol content in the
ER (cholesterol and/or oxysterols) must be decreasing rapidly
upon lymphocyte activation. Furthermore, the reduction in LXR
target gene expression during activation indicates that the nu-
clear availability of sterol LXR activators is also reduced. Indeed,
basal expression of LXR target genes in lymphocytes is depen-
dent on the production of endogenous LXR agonists by the
mevalonate pathway.
Unexpectedly, the mechanism by which LXR activity is regu-
lated during T cell activation does not involve alteration in ligand
production; rather, it is due to induction of enzymatic ligand me-
tabolism. The enzyme SULT2B1 transfers sulfate groups to
oxysterols, inactivates them as LXR ligands, and facilitates their
export from the cell. We have shown that expression of SULT2B1
is dramatically increased in T cells by proliferative stimuli. This
induction would be predicted to deplete the cell of LXR ligand
and suppress expression of LXR target genes (Chen et al.,108 Cell 134, 97–111, July 11, 2008 ª2008 Elsevier Inc.2007; Fuda et al., 2007). In fact, expression of SULT2B1 in rest-
ing lymphocytes with an adenoviral vector recapitulates the
effects of proliferative stimuli on both the LXR and SREBP
gene expression programs. Thus, upregulation of SULT2B1 dur-
ing cell proliferation provides an elegant mechanism to affect
changes in cellular cholesterol metabolism required to support
new membrane synthesis and cell division. Whether additional
mechanisms also contribute to regulation of LXR activity during
cell proliferation remains to be addressed.
The ability of ABCG1 expression to block proliferation impli-
cates a sterol substrate of this transporter in a metabolic
checkpoint that regulates cell-cycle progression. Early studies
on cholesterol synthesis in lymphocytes found that mani-
pulation of the mevalonate pathway by the addition of sterol me-
tabolites, such as 25-hydroxycholesterol, resulted in a G1 arrest
(Chakrabarti and Engleman, 1991). Similarly, HMG-CoA inhibi-
tors block the proliferation of cells in multiple systems. A compli-
cating factor in these studies is that suppression of the mevalo-
nate pathway also perturbs synthesis of nonsterol mevalonate
derivatives such as geranylgeraniol and farnesol. However, at-
tempts to uncouple the cholesterol synthetic pathway from non-
steroidal protein modifications either with low-dose statins or
inhibitors of downstream enzymes have revealed an absolute
requirement for cholesterol in cell-cycle progression and mitosis
(Martinez-Botas et al., 2001; Martinez-Botas et al., 1999). We
have observed a similar arrest in the cell cycle; however, our
gene profiling studies show that we are not blocking the
SREBP-2 pathway. Rather, we are likely enforcing sterol efflux
or redistribution, resulting in a localized depletion of sterols.
ABCG1 is known to play an important role in cholesterol and
oxysterol efflux (Kennedy et al., 2005; Terasaka et al., 2007;
Wang et al., 2004). Recent studies have also reported that
ABCG1 is found in intracellular compartments, such as the ER
and vesicles, and that ABCG1 expression stimulates SREBP-2
activity through the redistribution of sterols out of the ER (Tarr
and Edwards, 2007). We hypothesize that adequate levels of
one or more sterols in a particular cellular compartment, likely
the ER, are read by the cell-cycle machinery as an indication of
appropriate metabolic conditions for cell division. Downregula-
tion of ABCG1 during activation may be necessary to maintain
compartmentalization of these sterols. Forced induction of
ABCG1 by LXR activation reduces the availability of this signal-
ing sterol. In the absence of LXR, increased sterol levels act as
a stimulus to proliferation. At present, we favor the hypothesis
that cholesterol itself is the sterol being sensed by the cell-cycle
machinery, because the ability of LXR agonists to block prolifer-
ation indicates that the signaling sterol is not an LXR agonist.
In summary, this work outlines a previously unrecognized role
for LXRb and sterol signaling in the regulation of lymphocyte
function. Although our focus in this report has been on lympho-
cytes, the ability of the SULT2B1-LXR-ABCG1 axis to couple
cellular cholesterol metabolism and proliferation is likely to be
applicable to many cell types, particularly those undergoing
rapid cell division. Finally, given that LXR responds to endoge-
nous lipids whose availability may be altered in disease, our
results raise the possibility that LXR signaling may impact ac-
quired immune responses in human metabolic diseases such
as dyslipidemia and atherosclerosis.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6 and C57BL/6 recombination activating gene 1-deficient mice were
purchased from the Jackson Laboratory. Lxra and Lxrb null mice were a gift
from D. Mangelsdorf (University of Texas Southwestern) and are greater
than ten generations backcrossed to C57BL/6. BCL-xL transgenic mice
were a gift from D. Green (St. Jude’s). ABCG1 and ABCA1 null mice have
been previously described (Kennedy et al., 2005; Timmins et al., 2005).
Do11.10 CAR transgenic mice were purchased from the Taconic Laboratory.
All mice were maintained under pathogen-free (SPF) conditions in the animal
facilities of the University of California, Los Angeles (UCLA). TAP-deficient
MECs expressing the human adenovirus type 5 early region 1 (Ad5E1) have
been described (Schoenberger et al., 1998).
Media, Reagents, Antibodies, and Flow Cytometry
GW3965, T0901317, and GW7845 were provided by T. Willson and J. Collins
(GlaxoSmithKline). Lymphocytes were grown in RPMI 1640 supplemented
with 10% heat-inactivated FCS, 100 U/mL penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, 10 mM HEPES (all from GIBCO), and 50 mM 2-ME (Sigma-
Aldrich). 7-AAD, Propidium iodide, annexin V, anti-mouse CD25 (PC61), CD3
(2C11), CD4 (RM4-5), CD8 (53-6.7), CD28 (37.51), CD69 (HI.2F3), Foxp3
(FJK-16 s), and anti-human CD4 (RPA-T4), CD8 (RPA-T8), Ki-67 (B-56), and
PCNA (PC-10) were purchased from BD Biosciences and eBioscience. Puri-
fied anti-human CD3 (OKT3) was purchased from Ortho Scientific. Murine
rIL-2 was purchased from Peprotech. Flowbright counting beads (Invitrogen)
were added to FACS tubes before analysis to normalize CFSE dilution profiles.
Intracellular PCNA and Ki-67 staining was performed per the manufacturer’s
instruction (BD Biosciences). Cells were analyzed on FACSCalibur or LSR
(Becton Dickinson) with FlowJo software (Treestar).
Cell Purification and Cell Counts
In some experiments, mouse or human T cells were enriched with negative se-
lection. For mouse, T cell or B cell enrichment was performed with Pan T or B
cell isolation kit (Miltenyi Biotec) and selection onMidiMACS columns (Miltenyi
Biotec) per themanufacturer’s instructions. For human T cells, enrichment was
performed with Rosette Sep (Stem Cell Technologies) per the manufacturer’s
instructions. Purity was confirmed at > 95% by flow cytometry. Cells counts
were performed on an Improved Neubauer Hemacytometer with trypan blue
exclusion. All LN cell counts reported are from two inguinal and four axillary
LNs. For adenoviral transductions, purified CAR transgenic T cells were incu-
bated with adenovirus at a multiplicity of infection (MOI) of 10:1 for 1 hr in com-
plete media. Cells were then washed twice and resuspended at 1 3 106 cells
per mL in complete media.
Proliferation Studies
For 3H-thymidine incorporation studies, single-cell suspensions of murine
spleen were initially prepared with ACK lysis buffer. Whole spleen cells were
plated in 96-well round bottom plates (2 3 105 cells/well) and stimulated
with LPS (10 mg/mL), Concavalin A (10 mg/mL), anti-IgM (Fab’)2 (10 mg/mL),
or PMA (0.5 mM) and ionomycin (100 mM). Cells were cultured for 24–96 hr
at 37C and 5% CO2 and pulsed with
3H-thymidine for the final 16 hr. For
some studies, T cells or B cells were purified and enriched from spleen and
LNs by negative selection as indicated above. Single-cell suspensions were
labeled with CFSE (Molecular Probes) as described previously (Lyons and
Parish, 1994). Cells were stimulated as above. Human T cells were CFSE
labeled and stimulated with anti-CD3 (1 mg/mL) crosslinked with plate-bound
goat anti-mouse (100 mg/mL) in 96-well flat-bottom plates (23 105 cells/well).
Some cultures received 2 mg/well of soluble anti-CD28. Cells were stained for
surface expression of CD8 and CD4 on the indicated days, incubated with
7-AAD, and 5 3 104 counting beads were added to tubes before analysis by
flow cytometry.
Immunization and Homeostatic Proliferation Assays
For immunization studies, WT and Lxrb null mice were immunized subcutane-
ously with 13 107 irradiated (3000 rad) TAP-deficient mouse embryonic fibro-
blasts expressing Ad5E1. Mice were sacrificed on day 7, and antigen-specificCD8+ T cells were enumerated from spleen as described (Schoenberger et al.,
1998). Single-cell suspensions were incubated for 5 hr with E1B192–200 peptide
[(aa:VNIRNCCYI) A&A labs LLC)[ at 2.5 mg/mL in the presence of Brefeldin A
(BD Biosciences) ex vivo. Cells were stained for surface expression of CD8
and CD4, fixed, permeabilized with Cytofix/Cytoperm kit (BD Biosciences),
and stained for intracellular IFN-g and TNF-a according to the manufacturer’s
protocol. For homeostatic proliferation studies, 1 3 106 purified LXRb null
(Thy1.2+) T cells and WT (Thy1.1+) T cells were coadoptively transferred into
the same B6.RAG null host. Peripheral blood and spleen was harvested and
stained for CD3, and Thy1.1 expression was and analyzed by FACS.
RNA Isolation, DNA Microarray and Real-Time PCR Analysis
For DNA microarray, total RNA was isolated from cells with Trizol (Invitrogen)
and further purified with RNAeasy columns (QIAGEN). Preparation and hybrid-
ization to Affymetrix 430 v2.0 was performed at the UCLAmicroarray core and
data analyzed with GeneSpring GX 7.3 (Agilent Technologies). For real-time
PCR, total RNA was isolated as above. One microgram of total RNA was
reverse transcribed with random hexamers with the Taqman Reverse Tran-
scription Reagents Kit (Applied Biosystems). Sybergreen (Diagenode) real-
time quantitative PCR assays were performed with an Applied Biosystems
7900HT sequence detector. Results show averages of duplicate experiments
normalized to 36B4.
Protein Isolation and Analysis
Total cell lysates were prepared in lysis buffer (10 mM KCl, 1.5 mM MgCl2,
10 mM Tris-HCl [pH 7.4], 1% SDS) supplemented with protease inhibitors
(Roche Molecular Biochemicals). Samples were separated on a 12% SDS-
polyacrylamide gel and transferred to nitrocellulose. Membranes were probed
with anti-hLXRa and anti-hLXRb (Perseus Proteomics), anti-P27kip (Cell Sig-
naling) and anti-CDK4 (Santa Cruz Antibodies) at 1:1000 overnight to detect
expression. Goat anti-mouse and Donkey anti-rabbit (DAKO) were used at
1:3000 for 1 hr at room temperature and visualized with chemiluminescence
(ECL, Amersham Pharmacia Biotech).
Statistical Methods
Real-time PCRdata, in vitro proliferation assays, and cell counts are expressed
as the mean ± standard deviation. The frequency of antigen-specific T cells
and homeostatically proliferating T cells are presented as themean ± standard
error of the mean (SEM). All statistical analysis was done with the student’s
t test. A probability value of p < 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include eleven figures and can be found with this article
online at http://www.cell.com/cgi/content/full/134/1/97/DC1/.
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